Oct 1 2025

george

An Experimental Oral FVIII Mimetic

Click here in Hemostasis Today for a brief discussion of a developing phase 1 oral FVIII mimetic: Wolfgang Miesbach: Jan Astermark at the BIC 2025 presented Potentially the First Oral FVIII Mimetic Treatment for Hemophilia A.

read more

Comments (0)

Bleeding Disorders

Sep 25 2025

george

Incubation to Inactivate Efanesoctocog Alfa Prior to Inhibitor Bethesda Titer

Click here for an open-access letter that indicates the need to inactivate plasma EHL FVIII efanesoctocog alfa (Altuuviiio®; Altuvoct®) before performing a Bethesda titer to measure anti-FVIII inhibitor: Bowyer A. Is incubation for 30 minutes at 56°C sufficient to fully inactivate efanesoctocog alfa? Haemophilia. 2025. doi: 10.1111/hae.70137. PMID: 40985057. The findings provide a recommended incubation […]

read more

Comments (0)

Bleeding Disorders

Sep 24 2025

george

WFH Fibrinogen Disorders Booklet

Click here for a recent WFH booklet, What Are Fibrinogen Disorders?

read more

Comments (0)

Bleeding Disorders

Sep 17 2025

george

Effect of Rebalancing Therapy on Coagulation Assays

Click to read this open-access article that explores the effects of antithrombin reduction (rebalancing) hemophilia therapy on a series of coagulation tests: Chhabra, ES ; Liu, M. Evaluation of the interference of fitusiran and antithrombin lowering in plasma on routine coagulation assays. Research and practice in thrombosis and haemostasis, 2025;9:102989–9.

read more

Comments (0)

Bleeding Disorders

Sep 17 2025

george

A Review of Current and Developing DOAC Reversal Agents

Check with your medical library for this comprehensive review of current and developing DOAC reversal agents:  Gómez-Outes A, Suárez-Gea ML, Lecumberri R. When and how to use reversal agents for direct oral anticoagulants? Curr Cardiol Rep. 2023;25:371–80. doi: 10.1007/s11886-023-01858-x. PMID: 36976497. Abstract Purpose of review: Our objective is to describe currently available reversal agents for […]

read more

Comments (0)

Anticoagulant Therapy

Sep 10 2025

george

Poster: Monitoring FVIII in Hemophilia Patients Treated with Bypassing Therapeutics

To review the PBI poster presented at the 2025 ISTH meeting, click Effect of Mim8 and Emicizumab on Factor VIII Recovery by a Novel, Bovine Chromogenic FVIII Assay. Tara Quinton, Meghan Bruhm, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada. The poster illustrates the validity of bovine reagent-based chromogenic substrate FVIII […]

read more

Comments (0)

Bleeding Disorders

Aug 30 2025

george

NXT007: A First-in-human Study of a Factor Bypassing Hemophilia Therapy

Check with your medical library for a copy of  Sambe T, Miwa T, Yoneyama K, et al. A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants. J Thromb Haemost. 2025: S1538–7836(25)00399-X. doi: 10.1016/j.jtha.2025.06.013. PMID: 40554054. Here’s the abstract: Background: NXT007 is a bispecific antibody that mimics the cofactor function […]

read more

Comments (0)

Bleeding Disorders

Aug 15 2025

george

Hemophilia After 2014

I (Geo) just added an updated ~40-minute audio PowerPoint module that describes hemophilia therapy after 2014, including extended half-life concentrates, factor bypassing therapy, genetic transfer of F8 and F9 genes, and rebalancing therapy. The module ends with a discussion of the laboratory means for monitoring the new therapeutics. Navigate to Educational Modules and click Hemophilia […]

read more

Comments (0)

Bleeding Disorders

Aug 1 2025

george

Thrombotic Thrombocytopenic Purpura

Click “In Their Blood” for a review article about TTP from the University of Kansas (KU) Medical Center’s Pathology Department. The article highlights the early research into ADAMTS13‘s role in VWF metabolism, the early successes of PLEX therapy, and the current availability of the therapeutics caplacizumab and the ADAMTS13 concentrate, Adzynma. Also featured is the […]

read more

Comments (0)

Bleeding Disorders

Jul 29 2025

george

July 2025 QQ: Hemophilia Rebalancing Therapy

Our July 2025 Quick Question asked, “Which is a hemophilia ‘rebalancing’ therapeutic?” The question attracted a modest 22 participants, perhaps an indication that rebalancing therapy was only FDA-approved in 2025 and awaits approval in Canada and Europe. Here are your responses… Valoctocogene roxaparvovec-rvox (ROCTAVIAN) 3 (14%) Efanesoctocog alfa (ALTUVIIIO) 1 (4%) Emicizumab (HemLibra) 7 (32%) […]

read more

Comments (0)

Quick Question Archive